Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China
Qian Xu,
Chunli Wang,
Wei Cheng,
Yingzi Zhen,
Yaguang Ding,
Guoqing Liu,
Wanru Yao,
Zhenping Chen,
Zhiqiang Li,
Runhui Wu
Affiliations
Qian Xu
Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China; Department of Hematology & Oncology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 611731, China
Chunli Wang
Nursing Department, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, China
Wei Cheng
Department of Cardiovascular Surgery II, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, China
Yingzi Zhen
Nursing Department, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, China
Yaguang Ding
Nursing Department, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, China
Guoqing Liu
Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China
Wanru Yao
Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China
Zhenping Chen
Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China
Zhiqiang Li
Department of Cardiovascular Surgery II, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, China
Runhui Wu
Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China; Corresponding author. 56 Nanlishi Rd, Beijing 100045, China.
Objectives: To report the perioperative management experience of central venous access devices (CVAD) in Chinese children with severe hemophilia A (SHA) in China. Methods: This retrospective study included SHA children who underwent Port-A-Cath or peripherally inserted central catheter (PICC) implantation between 2020/01 and 2021/07. Collected data included baseline characteristics, factor replacement regimen and CVAD-related complications. Results: Nine patients had nine ports placed, and eight patients underwent 10 PICCs placement. Patients without or with low-titer inhibitor (10 BU) received PICC. The median recombinant factor VIIa (rFVIIa) dose was 87.47 μg/kg before and for 5–7 doses after implantation over 2–3 days. The median PICC duration was 226.5 days, with infection incidence of 0.12 per 1000 catheter-days. Conclusions: CVADs can be safely implanted in China. PICC implantation is a practical and safe option for SHA children with high-titer inhibitors.
